➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Express Scripts
Johnson and Johnson
McKesson
Colorcon

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,962,603

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,962,603 protect, and when does it expire?

Patent 8,962,603 protects ELLA and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,962,603
Title:Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.
Inventor(s): Levy; Delphine (Paris, FR), Ulmann; Andre (Paris, FR), Mathe; Henri Camille (Paris, FR), Gainer; Erin (Paris, FR)
Assignee: Laboratoire HRA-Pharma (Paris, FR)
Application Number:13/575,086
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,962,603
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,962,603

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Lab Hra Pharma ELLA ulipristal acetate TABLET;ORAL 022474-001 Aug 13, 2010 AB RX Yes Yes   Start Trial   Start Trial METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHTHAVING A BMI OF 25 TO 29.99   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,962,603

PCT Information
PCT FiledDecember 01, 2010PCT Application Number:PCT/EP2010/068646
PCT Publication Date:August 04, 2011PCT Publication Number: WO2011/091890

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
AstraZeneca
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.